| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept … C Le Tourneau, JP Delord, A Gonçalves, C Gavoille, C Dubot, N Isambert, ... The lancet oncology 16 (13), 1324-1334, 2015 | 1066 | 2015 |
| Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ... Jama 303 (17), 1729-1737, 2010 | 927 | 2010 |
| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma E Saâda-Bouzid, C Defaucheux, A Karabajakian, VP Coloma, V Servois, ... Annals of Oncology 28 (7), 1605-1611, 2017 | 585 | 2017 |
| EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype S Rebouissou, I Bernard-Pierrot, A de Reyniès, ML Lepage, C Krucker, ... Science translational medicine 6 (244), 244ra91-244ra91, 2014 | 363 | 2014 |
| Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program) S Beurtheret, P Mordant, X Paoletti, E Marijon, DS Celermajer, P Léger, ... European heart journal 34 (2), 112-120, 2013 | 277 | 2013 |
| Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units JC Lucet, X Paoletti, I Lolom, C Paugam-Burtz, JL Trouillet, JF Timsit, ... Intensive care medicine 31, 1051-1057, 2005 | 198 | 2005 |
| Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors B Geoerger, D Hargrave, F Thomas, A Ndiaye, D Frappaz, F Andreiuolo, ... Neuro-oncology 13 (1), 109-118, 2010 | 167 | 2010 |
| Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis K Oba, X Paoletti, S Alberts, YJ Bang, J Benedetti, H Bleiberg, P Catalano, ... Journal of the National Cancer Institute 105 (21), 1600-1607, 2013 | 162 | 2013 |
| Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities S Postel-Vinay, C Gomez-Roca, LR Molife, B Anghan, A Levy, I Judson, ... J Clin Oncol 29 (13), 1728-1735, 2011 | 145 | 2011 |
| Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide … A Lievre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... European Journal of Cancer 141, 62-81, 2020 | 141 | 2020 |
| COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area P Vuagnat, M Frelaut, T Ramtohul, C Basse, S Diakite, A Noret, ... Breast Cancer Research 22, 1-10, 2020 | 138 | 2020 |
| Statistical evaluation of surrogate endpoints with examples from cancer clinical trials M Buyse, G Molenberghs, X Paoletti, K Oba, A Alonso, W Van der Elst, ... Biometrical Journal 58 (1), 104-132, 2016 | 126 | 2016 |
| Operating characteristics of the standard phase I clinical trial design E Reiner, X Paoletti, J O'Quigley Computational Statistics & Data Analysis 30 (3), 303-315, 1999 | 125 | 1999 |
| Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents–dose … S Postel-Vinay, L Collette, X Paoletti, E Rizzo, C Massard, D Olmos, ... European Journal of Cancer 50 (12), 2040-2049, 2014 | 121 | 2014 |
| Leukocyte activation: the link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris MG Huisse, S Pease, M Hurtado-Nedelec, B Arnaud, C Malaquin, M Wolff, ... Critical care medicine 36 (8), 2288-2295, 2008 | 120 | 2008 |
| Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members JC Lucet, X Paoletti, C Demontpion, M Degrave, D Vanjak, C Vincent, ... Archives of internal medicine 169 (15), 1372-1378, 2009 | 110 | 2009 |
| Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials S Collette, F Bonnetain, X Paoletti, M Doffoel, O Bouché, JL Raoul, ... Annals of oncology 19 (6), 1117-1126, 2008 | 106 | 2008 |
| Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials N Houede, PF Thall, H Nguyen, X Paoletti, A Kramar Biometrics 66 (2), 532-540, 2010 | 104 | 2010 |
| Non‐parametric optimal design in dose finding studies J O'quigley, X Paoletti, J Maccario Biostatistics 3 (1), 51-56, 2002 | 104 | 2002 |
| Continual reassessment method for ordered groups J O'Quigley, X Paoletti Biometrics 59 (2), 430-440, 2003 | 102 | 2003 |
